지씨셀
Financials
Valuation Metrics
지씨셀's Market Cap is ₩2264B. At end of 2025 it was ₩3926B. Ranked #754 of 2,436 in KR market (top 31%), #330 of 1,649 on KOSDAQ (top 20%), #84 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 36%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 226.42B KRW | KR#754/2,436 Sec#84/234 |
| Revenue | 163.35B KRW | KR#1,118/2,436 Sec#68/234 |
| Net Income | -258.57B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 319.90B KRW | KR#983/2,436 Sec#63/234 |
| Net Assets | 190.38B KRW | KR#956/2,436 Sec#67/234 |
| Employees | 811 | KR#307/2,436 Sec#26/234 |
| Value | ||
| P/B | 1.19x | KR#1,633/2,436 Sec#111/234 |
| P/S | 1.39x | KR#1,613/2,436 Sec#94/234 |
| FCF Yield | 3.50% | KR#968/2,436 Sec#59/234 |
| Profitability | ||
| ROE | -135.82% | KR#2,361/2,436 Sec#222/234 |
| ROA | -80.83% | KR#2,376/2,436 Sec#226/234 |
| Op. Margin | -8.09% | KR#1,939/2,436 Sec#130/234 |
| Revenue Growth | -5.50% | KR#1,718/2,436 Sec#159/234 |
| Financial Health | ||
| Debt Ratio | 59.52% | KR#205/2,436 Sec#28/234 |
| Total Debt | 51.61B KRW | KR#973/2,436 Sec#66/234 |
| FCF | 7.92B KRW | KR#777/2,436 Sec#45/234 |
| Cash | 465.0M KRW | KR#2,372/2,436 Sec#228/234 |
| Current Ratio | 0.53x | KR#2,237/2,436 Sec#212/234 |
| Dividend | ||
| Div. Growth | -71.42% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -26.21% | KR#1,475/2,436 Sec#127/234 |
| 1M Return | -1.44% | KR#1,037/2,436 Sec#100/234 |
| From 52W High | -49.63% | KR#1,175/2,436 Sec#103/234 |
| 1Y MDD | -53.78% | KR#1,099/2,436 Sec#89/234 |
| Trading | ||
| Volume | 68,492 shares | KR#1,161/2,436 Sec#112/234 |
| Foreign Own. | 4.88% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -16,327 KRW | KR—/2,436 Sec—/234 |
| BPS | 12,178 KRW | KR#813/2,436 Sec#58/234 |
Company Info
Established in 2011 through the acquisition of a cell therapy business, this company expanded its operations by merging with Green Cross Cell in 2021. It encompasses the entire process of research and development, manufacturing, commercialization, and distribution within the cell and gene therapy field, offering cell therapies, specimen testing services, and bio-logistics. The company focuses on developing next-generation cell therapies such as CAR-NK and CAR-T, and is expanding indications to autoimmune diseases in collaboration with US company Artiva.